222 related articles for article (PubMed ID: 26832773)
41. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Tomsic J; He H; de la Chapelle A
N Engl J Med; 2015 Nov; 373(21):2086. PubMed ID: 26581005
[No Abstract] [Full Text] [Related]
42. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Sponziello M; Durante C; Filetti S
N Engl J Med; 2015 Nov; 373(21):2085-6. PubMed ID: 26581004
[No Abstract] [Full Text] [Related]
43. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Zhou EY; Lin Z; Yang Y
N Engl J Med; 2015 Nov; 373(21):2084-5. PubMed ID: 26581003
[No Abstract] [Full Text] [Related]
44. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Zhao X; Li X; Zhang X
N Engl J Med; 2015 Nov; 373(21):2084. PubMed ID: 26581002
[No Abstract] [Full Text] [Related]
45. HABP2 Mutation and Nonmedullary Thyroid Cancer.
Gara SK; Kebebew E
N Engl J Med; 2015 Nov; 373(21):2086-7. PubMed ID: 26581001
[No Abstract] [Full Text] [Related]
46. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population.
Uchino S; Noguchi S; Kawamoto H; Yamashita H; Watanabe S; Yamashita H; Shuto S
World J Surg; 2002 Aug; 26(8):897-902. PubMed ID: 11965446
[TBL] [Abstract][Full Text] [Related]
47. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
48. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.
Mazeh H; Benavidez J; Poehls JL; Youngwirth L; Chen H; Sippel RS
Thyroid; 2012 Jan; 22(1):3-8. PubMed ID: 22136209
[TBL] [Abstract][Full Text] [Related]
49. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity.
Capezzone M; Marchisotta S; Cantara S; Busonero G; Brilli L; Pazaitou-Panayiotou K; Carli AF; Caruso G; Toti P; Capitani S; Pammolli A; Pacini F
Endocr Relat Cancer; 2008 Dec; 15(4):1075-81. PubMed ID: 18832444
[TBL] [Abstract][Full Text] [Related]
50. HABP2 in Familial Non-medullary Thyroid Cancer: Will the Real Mutation Please Stand Up?
Ngeow J; Eng C
J Natl Cancer Inst; 2016 Jun; 108(6):djw013. PubMed ID: 26832774
[No Abstract] [Full Text] [Related]
51. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
52. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
53. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
[TBL] [Abstract][Full Text] [Related]
54. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
[TBL] [Abstract][Full Text] [Related]
55. Clinical Analysis of Familial Nonmedullary Thyroid Carcinoma.
Zhang Q; Yang S; Meng XY; Chen G; Pang RZ
World J Surg; 2016 Mar; 40(3):570-3. PubMed ID: 26711636
[TBL] [Abstract][Full Text] [Related]
56. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2.
Canzian F; Amati P; Harach HR; Kraimps JL; Lesueur F; Barbier J; Levillain P; Romeo G; Bonneau D
Am J Hum Genet; 1998 Dec; 63(6):1743-8. PubMed ID: 9837827
[TBL] [Abstract][Full Text] [Related]
57. Genetic aspects of familial thyroid cancer.
Morrison PJ; Atkinson AB
Oncologist; 2009 Jun; 14(6):571-7. PubMed ID: 19465682
[TBL] [Abstract][Full Text] [Related]
58. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
59. The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.
Park YJ; Ahn HY; Choi HS; Kim KW; Park DJ; Cho BY
Thyroid; 2012 Apr; 22(4):356-62. PubMed ID: 22280228
[TBL] [Abstract][Full Text] [Related]
60. Genetic predisposition to papillary thyroid cancer.
Kula D; Kalemba M; Jurecka-Lubieniecka B; Puch Z; Kowalska M; Tyszkiewicz T; Kowal M; Handkiewicz-Junak D
Endokrynol Pol; 2010; 61(5):486-9. PubMed ID: 21049463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
